BioRestorative Therapies (BRTX) Non-Current Assets (2010 - 2025)
BioRestorative Therapies' (BRTX) quarterly Non-Current Assets came in at $942773.0 in Q4 2025, down 16.98% YoY from $1.1 million in Q4 2024, and up 0.81% on a QoQ basis from $935198.0 in Q3 2025.
BioRestorative Therapies (BRTX) Non-Current Assets (2010 - 2025) Analysis & Trends
BioRestorative Therapies (BRTX) has 16 years of Non-Current Assets data on file, last reported at $942773.0 in Q4 2025.
- Quarterly Non-Current Assets fell 16.98% year-over-year to $942773.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $3.8 million (down 16.2% YoY) and the FY2025 annual result came in at $942773.0, down 16.98% from the prior year.
- Non-Current Assets improved to $942773.0 in Q4 2025, from $935198.0 in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $1.3 million in Q4 2022 to a low of $918752.0 in Q2 2025.
- A 5-year average of $1.1 million and a median of $1.1 million in 2021 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2022 — Non-Current Assets soared 32.54% — and 2025, when it declined 17.75%.
- Tracing BRTX's Non-Current Assets over 5 years: stood at $985538.0 in 2021, then soared by 32.54% to $1.3 million in 2022, then retreated by 6.51% to $1.2 million in 2023, then fell by 7.01% to $1.1 million in 2024, then fell by 16.98% to $942773.0 in 2025.
- The last three Non-Current Assets figures came in at $942773.0 (Q4 2025), $935198.0 (Q3 2025), and $918752.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 938.60 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 468.65 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 18.06 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 6.80 Bn |
| 10 | BioRestorative Therapies | 2.00 Mn | -953,752.60 | 17,964.00 | 942,773.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 942,773.00 |
| Sep 30, 2025 | 935,198.00 |
| Jun 30, 2025 | 918,752.00 |
| Mar 31, 2025 | 971,500.00 |
| Dec 31, 2024 | 1.14 Mn |
| Sep 30, 2024 | 1.06 Mn |
| Jun 30, 2024 | 1.12 Mn |
| Mar 31, 2024 | 1.18 Mn |
| Dec 31, 2023 | 1.22 Mn |
| Sep 30, 2023 | 1.20 Mn |
| Jun 30, 2023 | 1.26 Mn |
| Mar 31, 2023 | 1.30 Mn |
| Dec 31, 2022 | 1.31 Mn |
| Sep 30, 2022 | 1.03 Mn |
| Jun 30, 2022 | 1.12 Mn |
| Mar 31, 2022 | 1.04 Mn |
| Dec 31, 2021 | 985,538.00 |
| Sep 30, 2021 | 1.01 Mn |
| Jun 30, 2021 | 1.06 Mn |
| Mar 31, 2021 | 1.11 Mn |